Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

Summary Background Ustekinumab is a fully human anti‐p40 monoclonal antibody which neutralizes interleukin (IL)‐12 and IL‐23, thereby interfering with T‐helper (Th)1/Th17 pathways and keratinocyte activation, and is highly effective in the treatment of psoriasis. During ustekinumab treatment, some...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2013-05, Vol.168 (5), p.990-998
Hauptverfasser:	Baerveldt, E.M., Onderdijk, A.J., Kurek, D., Kant, M., Florencia, E.F., Ijpma, A.S., van der Spek, P.J., Bastiaans, J., Jansen, P.A., van Kilsdonk, J.W.J., Laman, J.D., Prens, E.P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Antimicrobial Cationic Peptides - genetics Biological and medical sciences Dermatologic Agents - therapeutic use Dermatology Female GATA3 Transcription Factor - genetics Gene Expression Regulation Humans Interleukin-12 - immunology Interleukin-23 - immunology Leukocyte Count Male Medical sciences Middle Aged Nerve Growth Factor - genetics Psoriasis - drug therapy Psoriasis - genetics Psoriasis. Parapsoriasis. Lichen Receptors, Interleukin - genetics RNA, Messenger - metabolism Severity of Illness Index Skin - drug effects Treatment Outcome Ustekinumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!